Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
The University of Leicester has joined forces with Cambridge-based Isogenica to develop new immunotherapies – a process where the patient’s immune system is helped to fight cancer – which will be tested on a ‘virtual patient’.